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Abstract
Background: Sclerosing hemangioma (SH) of the lung is a kind of rare pulmonary tumor. Preoperative diagnosis of
this tumor is difficult and it is now generally accepted that SH of the lung is benign lesions and surgical excision
alone is curative. Herein, we present our experiences of treating 28 patients with SH.
Methods: The medical records of 28 patients with SH from 1994 to 2010 at the Department of Thoracic Surgery in
Beijing Chest Hospital were retrospectively reviewed.
Results: There were 3 male and 25 female patients with sclerosing hemangioma and 50% of the patients were
asymptomatic. Preoperatively, all the patients had undergone CT of chest and 5 patients had undergone PET scan
but 4 patients were misdiagnosed as malignancy. There was no operative mortality or tumor recurrence despite
that three different operative methods were undertaken.
Conclusions: SH has a high incidence in middle-aged women. Most of SH is asymptomatic and the symptoms of
SH are not related to the tumor size and distribution. The features of chest CT and PET are not specific. Bilateral or
multiple lesions should not exclude the possibility of SH. Complete excision of lesion is a curable treatment method
and there is no evidence to verify the need of adjuvant therapy.
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Background
Sclerosing hemangioma (SH) of the lung is a kind of
rare pulmonary tumor which was first reported in 1956
by Liebow and Hubbel [1]. SH is composed of four
histologic patterns including papillary, sclerotic, solid and
hemorrhagic. At first the tumor was thought to be endo-
thelial in origin, recently histochemical and ultrastructure
studies suggested an epithelial (type II pneumocyte)origin
[2]. Sclerosing hemangioma occurs in a wide age range
(11-83 age)but is more common in middle-aged women
[3,4] and has a higher incidence in Asia.
It is now generally accepted that sclerosing hemangioma
of the lung is benign lesions and surgical excision alone is
curative. This report describes our experience of surgery
treatment of 28 patients with sclerosing hemangioma.
Methods
From March 1994 to July 2010, 28 patients with scleros-
ing hemangioma underwent surgical treatment at the
Division of Thoracic Surgery in Beijing Chest Hospital.
Their medical records, operative procedures, histological
examinations and follow-up data were reviewed. Before
reviewed the data, we had obtained the approval of my
institutional review board. The relation between the dia-
meters of the tumors and the possibility of presenting
symptoms was estimated using the Logistic regression by
SPSS program, version 13.0. The frequency difference of
presenting symptoms in the patients which the tumors
located near the hilus of the lung and the other patients
was estimated using the χ
2 test(SPSS version 13.0).
Results
Clinical features
There were 3 male and 25 female patients with sclerosing
hemangioma. The age at the time of diagnosis ranged from
25 to 58 years(mean age was 46.1 years). There were 14
patients who had no symptom and find the tumor on rou-
tine checkup. Among the symptomatic patients 7 presented
with hemoptysis, 9 presented with cough, 3 presented with
chest pain, 1 presented with expectoration sputum and 1
presented with fever.
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bility of presenting symptoms using the Logistic regression
(SPSS version 13.0), the P value was 1.000 and suggested
that the symptoms were not related to the tumor size.
According to the location of the tumors, we divided the
patients into two groups: central group(underwent lobec-
tomy because of the near hilus location of the tumors) and
peripheral group. The frequency of presenting symptoms
showed no difference between the two groups (Table 1).
Radiographic features
All but one patient had a solitary tumor on chest roent-
genograms: 3 tumors located at left upper lobe, 9 tumors
located at left lower lobe, 5 tumors located at right upper
lobe, 4 tumors located at right middle lobe and 6 tumors
located at right lower lobe. The exceptional patient had
one major tumor which was 5.5 cm in diameter, located
at left lower lobe and had multiple smaller tumors scat-
tering at right lower lobe and left lower lobe.
Computer tomography (CT) scan of chest was per-
formed in all the 28 patients. Solitary tumor was found
in 27 patients. Among them malignancy was suspected
in 3 patients for notch sign and spicular sign, the other
patients were diagnosed as having benign lesions. In 1
patient, multiple tumors were found and diagnosed as
metastases.
Positron emission tomography (PET) was performed in
5 patients. Among them, hyper metabolic lesions (SUV
was 3.35>the cut-off value 2.5) were found in the pa-
tient who had bilateral multiple tumors. There were no
hypermetabolic lesions in PET of the other 4 patients.
Operations
There were three types of operation methods we used.
Enucleation was the most common procedure per-
formed, 13 patients underwent the operation accounted
for 46.4% of the patients. 7 patients underwent wedge re-
section accounted for 25% of the patients. We performed
lobectomy in the other 8 patients(accounted for 28.6% of
the patients) for the central locations of the tumors. One
patient was diagnosed metastases because of the multiple
tumors in bilateral lungs. This patient underwent video-
assisted thoracoscopic surgery (VATS) wedge resection
and obtain two tumors of the left lower lobe, both the
tumors were diagnosed as sclerosing hemangioma (SH).
There were no operative mortality and morbidity.
None of the patients underwent adjuvant therapy.
During the follow-up ranging from 6 months to 16 years,
none of the patients experienced tumor recurrence in-
cluding the patients with multiple tumors.
Discussion
Sclerosing hemangioma (SH) is more common in Asia
and most patients with SH are women in the fifth dec-
ade. Some authors suggested that once a middle-aged
Chinese women presents with a well-defined coin lesion
on the chest film SH should be considered first [5]. In
the current series, 89.3% of the patients were female and
34.6% of the patients aged from 40-49 ages. This data
was compatible with most reports.
It is reported that SH of the lung were mainly found
incidentally, over 70% of the patients were asymptomatic.
The common symptoms of SH include hemoptysis,
chronic cough and chest pain. In the current series, 50%
of the patients presented some symptoms including
hemoptysis, cough, chest pain, expectoration and fever.
Some symptoms such as expectoration and fever were
rarely seen in previously reports. The reason for more
patients of our series presented symptoms than the other
reports are not clear, we thought lack of regular body
checkup could be related with the difference.
Some authors believed the symptoms were due to en-
largement of the tumor and compression of surrounding
tissue, and some other authors thought they were not
related to tumor size or distribution [5-8]. To determine
the relation between the symptoms and diameters of
tumors, we analyzed the diameters of the tumors and the
possibility of presenting symptoms using the Logistic re-
gression(SPSS version 13.0)and found that the symptoms
were not related to the tumor size. In our series 8 patients
underwent lobectomy because the tumor located near to
the hilus of the lung. So we divided all the patients into
two groups: these 8 patients need lobectomy belonged to
the central group and the other patients who underwent
enucleation or wedge resection belonged to the peripheral
group. To determine the relation between the locations
and the symptoms, we estimated the frequency difference
of presenting symptoms in the two groups using the χ
2
test(SPSS version 13.0). We found that the frequencies of
presenting symptoms did not differ between the two
groups. Therefore we agreed that the symptoms of SH
were not related to the tumor size and distribution.
On chest radiographs, SH is usually a peripheral, solitary
nodule or mass with smooth margins. Calcification is sel-
dom seen and cavitation does not occur. Some CTfeatures
of SH were demonstrated including inhomogeneous en-
hancement, the tail sign, the prominent pulmonary-artery
sign, calcification, the air-trapping sign and so on, but
none of them were specific for SH [9,10]
. Of all these 28
patients, most patients (20/28) presented a peripheral, soli-
tary lesion with smooth margins on the chest radiographs
Table 1 The comparison of the frequencies of presenting
symptom in the central group and peripheral group
Without symptom With symptoms χ
2 P
Central group 3 5 0.700 0.678
Peripheral group 11 9
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(inhomogeneous enhancement in 18 patients, the tail sign
in 15 patients, the prominent pulmonary-artery sign in 10
patients, calcification in 3 patients and the air-trapping
sign in 3 patients). But because of the poor specificity of
the radiological features for SH, few of the patients were
diagnosed as SH directly and most of the patients were
diagnosed as benign lesions. So from previously reports as
well as our experience, it is believed that most patients
with SH could be diagnosed as benign lesions through the
chest radiographs and CT but it is difficult to confirm the
diagnosis as SH. Recently, fluorodeoxyglucose (FDG)-
positron emission tomography (PET) is being used more
and more to differentiate benign from malignant pulmon-
ary lesions and it has been shown to be more efficacious
than conventional chest CT. Since SH is thought to be a
kind of benign tumor, the standard uptake value(SUV)of it
should be less than 2.5 and then could be distinguished
from lung cancer or other malignant tumors. But in fact,
FDG is not a cancer-specific agent and some benign dis-
eases including SH could show false-positive results on
PET [11]. There have been some published reports about
pulmonary SH with increased uptake on PET scan, and
some authors thought the high uptake should be related
to the tumor size or the potentially low-grade malignant
nature of SH [12-15]. We performed PET scan on five
patients, and found SUV of the patient who had bilateral
multiple tumors and the largest tumor of the patient was
5.5 cm in diameter was greater than 2.5. Because of the
small number of the patients undergone PET scan our ex-
perience of it was limited, but we thought the high uptake
on PET scan cannot be used to exclude the diagnosis of
SH and may be related to the tumor size or the potentially
low-grade malignant nature of SH.
Traditionally, SH is a solitary lesion and thought to be
benign. However, several reports about SH with lymph
node metastasis, multiple and bilateral SH, recurrence of
SH and SH with pulmonary metastasis have published in
recent years [6,16-23]. These data suggested that SH may
be potential malignant, but most authors believed that
lymph node metastasis, multiple lesions, recurrence and
pulmonary metastasis did not affect the prognosis. In the
current series, chest CT of one patient showed bilateral
multiple tumors in left and right lower lobe. Because of
the multiple lesions the patient was diagnosed as metasta-
sis. We performed VATS wedge resection on this patient
and got two tumors of left lower lobe, both of them were
diagnosed as SH. Thinking of the same nature of the other
tumors, we did not resect them. After the operation, the
patient did not receive any adjuvant therapy. Until now,
15 months later, the residual lesions have not changed. So
we thought bilateral or multiple SH may be not related to
the prognosis. But we have no experience of SH with
lymph node or pulmonary metastasis and recurrence.
Conclusion
Our data suggest that SH has a high incidence in mid-
dle-aged women. Most of SH is asymptomatic and the
symptoms of SH are not related to the tumor size and
distribution. Chest CTand PET can offer some informa-
tion to diagnose accurately but the features are not
specific. Bilateral or multiple lesions should not exclude
the possibility of SH. Complete excision of lesion is a
curable treatment method and there is no evidence to
verify the need of adjuvant therapy.
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